Annexin V Inhibitors

Common Annexin V Inhibitors include, but are not limited to Camptothecin CAS 7689-03-4, Actinomycin D CAS 50-76-0, D,L-Sulforaphane CAS 4478-93-7, Etoposide (VP-16) CAS 33419-42-0 and Bortezomib CAS 179324-69-7.

Annexin V, a member of the annexin family of calcium-dependent phospholipid-binding proteins, plays a significant role in various cellular processes, including anti-inflammatory responses, anticoagulation, and apoptosis. Structurally characterized by its core domain comprising four annexin repeats, Annexin V possesses the unique ability to bind to phosphatidylserine (PS) in a calcium-dependent manner. Phosphatidylserine, typically found on the inner leaflet of the plasma membrane, gets externalized to the outer leaflet during apoptosis. Annexin V's affinity for PS has thus been utilized as a hallmark for detecting early apoptotic cells, as the protein can bind to externalized PS, marking these cells.

Annexin V inhibitors are molecules designed to modulate the binding capability or functionality of Annexin V. These inhibitors may achieve this by directly interacting with Annexin V, altering its conformation, and preventing its binding to phosphatidylserine. Alternatively, these inhibitors could interfere with the calcium-dependent binding mechanism that Annexin V relies upon. The inhibition of Annexin V binding to PS can influence the processes in which the protein is involved, such as the aforementioned anti-inflammatory responses, anticoagulation, and apoptosis detection. Moreover, given Annexin V's role as a biological marker for apoptosis, its inhibitors could impact the accurate identification of apoptotic cells. The study and understanding of Annexin V inhibitors provide a deeper insight into the multifaceted roles of Annexin V within cellular processes and its significance in cell biology. Such inhibitors offer a tool for dissecting the intricate interactions and functionalities of this pivotal protein.